肾癌的分子靶向治疗

Targeted molecular therapy for renal cell carcinoma

随着对肾癌发病机制包括细胞学、分子生物学研究的不断深入,肾癌发生中细胞信号转导通路中的一些关键分子成为治疗的靶点。以VEGF、VEGFR等为靶点的肾癌靶向治疗药物,如贝伐单抗、苏尼替尼、索拉非尼等在临床试验中已显示出很好的疗效。现就肾癌的分子靶向治疗的分子机理、临床试验研究、评价标准变化及应用前景作一简介。

Recent advances in the molecular biology of renal cell carcinoma have identified several important pathways that can be targeted for molecular therapy. Several anti-VEGF agents such as bevacizumab and the small molecule inhibitors of VEGF receptors such as sunitinib and sorafenib, have demonstrated activity in patients with metastatic RCC. In this review, we summarize the relevant biology , recent clinical trials, change of evaluation standard and potential future direction of targeted molecular therapy for renal cell carcinoma.